ST. LOUIS (March 26, 2018) – Tropichem Research Labs, LLC has acquired Montreal, Quebec-based TetraGenx (TGX), a leading independent animal health contract development and manufacturing organization (CDMO). TGX employees will continue to operate from its lab facility in Montreal, Quebec.
TGX (www.tetragenx.com) specializes in complex drug product formulation development, working as a subcontractor to develop innovative, over-the-counter, and nutraceutical veterinary pharma products. The Company’s services encompass four main categories, including product development (pre-formulation, formulation, and analytical development); analytical testing; manufacturing; and ancillary support services.
Kevin McDonnell, President, TGX said, “We are excited to partner with the Tropichem team to expand our capabilities and provide exclusive independent drug development and contract manufacturing for the animal health industry. Tropichem is a great complement to the TGX brand and mission.”
John Kane, CEO, Tropichem said, “The addition of TetraGenx to Tropichem gives us much-expanded service capabilities and reach in the animal health industry. TGX has long been known to us for their management’s commitment to excellence and quality. We’re very excited to have them become part of the team.”